Korsana Biosciences, Inc. (KRSA)
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules that act synergistically with nitric oxide on sGC to boost production of cyclic guanosine monophosphate. The company was founded on September 6, 2018 and is headquartered in Cambridge, MA.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Korsana Biosciences, Inc.
NASDAQ:KRSAHealthcare · Medical - Pharmaceuticals
-6.34%$31.31
AH Close$31.31+0.00%vs close
AH Close$31.31+0.00%vs close
Mkt Cap$1.43B
Float2.37M
O/S45.54M
Inst Own1.0%
SI0.5%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$2.07M
Net Income-$3.53M
Total Assets$9.98M
Free Cash Flow-$3.31M
Debt & Equity
Equity 100%
Total Debt$0
Total Equity$9.09M
Shares Outstanding
Short Interest
Split History2 splits · 2 reverse
2-year cumulative
1:49
Nasdaq bars a compliance period at 1:250
- 1:7Reverse splitSep 9, 20267 shares → 1
- 1:7Reverse splitSep 9, 20267 shares → 1
Balance Sheet Details
Assets$9.98M
Liabilities$900K
Accounts Receivable$1M
Accounts Payable$508K
Inventory$0
PP&E (Net)$0
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
| Revenue | $2.07M | $2M | $0 | $297K | $3.32M | $2.3M | $4.51M | $0 | $0 | $0 |
| YoY Growth | 3.7% | - | - | -91.1% | 44.6% | -49.1% | - | - | - | - |
| Cost of Revenue | $0 | $0 | $1.31M | $5.58M | $0 | $56.41M | $95.14M | $1.53M | $1.75M | $2.17M |
| Gross Profit | $2.07M | $2M | -$1.31M | -$5.28M | $3.32M | -$54.12M | -$90.63M | -$1.53M | -$1.75M | -$2.17M |
| Gross Margin | 100.0% | 100.0% | - | -1778.5% | 100.0% | -2357.1% | -2010.9% | - | - | - |
| Research and Development | $959K | $286K | $1.51M | $5.98M | $37.64M | $56.41M | $95.14M | $87.72M | $78.8M | $50.9M |
| Selling, General, and Administrative | $6.09M | $5.34M | $8.33M | $13.26M | $20.62M | $28.82M | $34.4M | $27.54M | $15.12M | $10.48M |
| Other | $0 | $0 | $1.79M | -$5.98M | $259K | -$58.08M | -$95.14M | $0 | $0 | $0 |
| Total Operating Expenses | $7.05M | $5.63M | $11.64M | $13.26M | $58.52M | $27.15M | $34.4M | $115.25M | $93.92M | $61.38M |
| Operating Income (EBIT) | -$4.97M | -$3.63M | -$12.95M | -$18.54M | -$55.2M | -$81.27M | -$125.04M | -$115.25M | -$93.92M | -$63.55M |
| Operating Margin | -239.8% | -181.4% | - | -6242.4% | -1662.5% | -3539.4% | -2774.3% | - | - | - |
| Interest Expense | $0 | $0 | $0 | $0 | $16K | $0 | $0 | $0 | $0 | $0 |
| Interest Income | $128K | $208K | $358K | $294K | $0 | $588K | $2.03M | $0 | $0 | $0 |
| Other Income (Expense) | $1.45M | $571K | $358K | $294K | $3.55M | $3.46M | $2.03M | $0 | $0 | $0 |
| Income Before Tax (EBT) | -$3.53M | -$3.06M | -$12.59M | -$18.25M | -$51.65M | -$77.8M | -$123.01M | -$115.25M | -$93.92M | -$63.55M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$3.53M | -$3.06M | -$5.26M | -$44.08M | -$51.65M | -$77.8M | -$123.01M | -$115.25M | -$93.92M | -$63.55M |
| Net Income Margin | -170.1% | -152.8% | - | -14841.1% | -1555.6% | -3388.6% | -2729.3% | - | - | - |
| Supplementary Data | ||||||||||
| EPS | -7.63 | -8.47 | -62.93 | -141.05 | -184.80 | -334.60 | -618.59 | -590.94 | -481.60 | -324.73 |
| Diluted EPS | -7.63 | -8.47 | -62.93 | -141.05 | -184.80 | -334.60 | -618.59 | -590.94 | -481.60 | -324.73 |
| Weighted Average OS | 460,714 | 359,714 | 334,000 | 310,429 | 279,600 | 217,164 | 195,571 | 195,032 | 195,029 | 195,726 |
| EBITDA | -$3.53M | -$3.06M | -$9.58M | -$18.18M | -$53.84M | -$80.64M | -$122.34M | -$113.72M | -$92.18M | -$61.38M |
| EBITDA Margin | -170.1% | -152.8% | - | -6121.5% | -1621.7% | -3512.1% | -2714.4% | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Assets | |||||||||
| Current Assets | |||||||||
| Cash and Cash Equivalents | $3.24M | $3.23M | $7.57M | $13.38M | $53.96M | $54.4M | $97.59M | $0 | $0 |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $3.24M | $3.23M | $7.57M | $13.38M | $53.96M | $54.4M | $97.59M | $0 | $0 |
| Accounts Receivable | $1M | $556K | $0 | $96K | $100K | $127K | $1.47M | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $928K | $0 | $0 | $0 | $0 |
| Other Current Assets | $11K | $16K | $11K | $537K | $468K | $1.56M | $162K | $12K | $8K |
| Total Current Assets | $4.63M | $4.22M | $8.02M | $14.82M | $55.46M | $58.5M | $101.2M | $879K | $1.26M |
| Long-Term Assets | |||||||||
| Property, Plant & Equipment Net | $0 | $0 | $0 | $1.22M | $1.47M | $50.27M | $79.75M | $6.5M | $4.13M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $5.35M | $5.35M | $5.35M | $0 | $0 | $0 | $4.99M | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $0 | $0 | $2.04M | $2.41M | $6.61M | $540K | $25K | $80K |
| Total Long-Term Assets | $5.35M | $5.35M | $5.35M | $3.26M | $3.87M | $56.88M | $85.28M | $6.52M | $4.21M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $9.98M | $9.57M | $13.37M | $18.08M | $59.33M | $115.38M | $186.48M | $7.4M | $5.47M |
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts Payable | $508K | $390K | $1.2M | $2.97M | $1.83M | $1.15M | $3.31M | $2.78M | $1.8M |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $3.51M | $3.42M | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $51K | $63K | $102K | $68K | $7.28M | $176K | $5.05M | $7.27M | $5.62M |
| Total Current Liabilities | $900K | $725K | $2.09M | $7.63M | $11.09M | $16.95M | $18.25M | $17.85M | $14.04M |
| Long-Term Liabilities | |||||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Long-Term Liabilities | $0 | $0 | $0 | $0 | $0 | $38.93M | $70.5M | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $900K | $725K | $2.09M | $7.63M | $11.09M | $55.88M | $88.75M | $17.85M | $14.04M |
| Stockholders' Equity | |||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Retained Earnings | -$271.02M | -$267.49M | -$264.42M | -$259.15M | -$215.08M | -$163.43M | -$85.63M | $0 | $0 |
| Comprehensive Income & Other | $0 | $0 | -$12K | -$20K | -$23K | -$27K | -$20K | -$15.49M | -$15.87M |
| Other Stockholders' Equity | $280.11M | $276.34M | $275.7M | $269.61M | $263.32M | $222.92M | $183.36M | -$10.45M | -$8.57M |
| Total Equity | $9.09M | $8.85M | $11.29M | $10.45M | $48.25M | $59.49M | $97.73M | -$10.45M | -$8.57M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $9.98M | $9.57M | $13.37M | $18.08M | $59.33M | $115.38M | $186.48M | $7.4M | $5.47M |
| Supplementary Data | |||||||||
| Total Debt | $0 | $0 | $0 | $0 | $0 | $45.73M | $73.92M | $0 | $0 |
| Net Debt | -$3.24M | -$3.23M | -$7.57M | -$13.38M | -$53.96M | -$8.66M | -$23.68M | $0 | $0 |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
| Operating Activities | ||||||||||
| Net Income | -$3.53M | -$3.06M | -$12.59M | -$18.25M | -$51.65M | -$77.8M | -$123.01M | -$115.25M | -$93.92M | -$63.55M |
| Depreciation & Amortization | $0 | $0 | $65K | $65K | $472K | $2.3M | $2.7M | $1.53M | $1.75M | $2.17M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $441K | $625K | $0 | $0 | $9.61M | $14.99M | $19.63M | $12.43M | $9.49M | $0 |
| Changes in Working Capital: | ||||||||||
| Accounts Receivable | -$444K | -$556K | $96K | $4K | $27K | $1.35M | -$1.47M | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | -$3.18M | $0 | $0 | $0 |
| Accounts Payable | $118K | -$445K | -$1.77M | $1.14M | $393K | -$1.1M | -$250K | $979K | $392K | $508K |
| Other Working Capital | $99K | -$537K | -$2.92M | -$4M | $988K | -$7.84M | $2.61M | $2.81M | $1.07M | $3.82M |
| Total Working Capital Change | -$227K | -$1.54M | -$4.6M | -$2.85M | $1.41M | -$7.59M | -$2.29M | $3.79M | $1.47M | $4.33M |
| Other Non-Cash Items | $0 | -$363K | -$4.12M | -$19.58M | $3.64M | -$4.38M | $751K | $14.51M | $12.59M | $11.02M |
| Net Cash from Operating | -$3.31M | -$4.33M | -$21.25M | -$40.61M | -$36.52M | -$72.49M | -$102.22M | -$97.5M | -$81.22M | -$49.87M |
| Investing Activities | ||||||||||
| Capital Expenditures | $0 | $0 | $0 | $0 | -$7K | -$1.52M | -$6.89M | -$3.44M | -$1.4M | -$1.45M |
| Acquisitions | $0 | $0 | $10.4M | $0 | $0 | $0 | $173K | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $1.46M | $1.54M | $173K | $0 | $0 | $0 |
| Net Cash from Investing | $0 | $0 | $10.4M | $0 | $1.46M | $18K | -$6.71M | -$3.44M | -$1.4M | -$1.45M |
| Financing Activities | ||||||||||
| Debt Repaid | - | - | - | - | - | - | - | - | - | - |
| Common Stock Issuance | $1.38M | $0 | $5.02M | $29K | $30.5M | $24.25M | $175M | $0 | $0 | $0 |
| Common Stock Repurchases | -$130K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $2.08M | $0 | $0 | $0 | $282K | $331K | $36.57M | $100.94M | $82.62M | $51.32M |
| Net Cash from Financing | $3.32M | $0 | $5.02M | $29K | $30.79M | $28.09M | $211.57M | $100.94M | $82.62M | $51.32M |
| Forex Effect | $0 | -$6K | $8K | $3K | $4K | -$7K | -$20K | $0 | $0 | $0 |
| Net Change in Cash | $8K | -$4.34M | -$5.81M | -$40.58M | -$4.27M | -$44.39M | $102.62M | $0 | $0 | $0 |
| Supplementary Data | ||||||||||
| Operating Cash Flow | -$3.31M | -$4.33M | -$21.25M | -$40.61M | -$36.52M | -$72.49M | -$102.22M | -$97.5M | -$81.22M | -$49.87M |
| Capital Expenditure | $0 | $0 | $0 | $0 | -$7K | -$1.52M | -$6.89M | -$3.44M | -$1.4M | -$1.45M |
| Free Cash Flow | -$3.31M | -$4.33M | -$21.25M | -$40.61M | -$36.52M | -$74.01M | -$109.1M | -$100.94M | -$82.62M | -$51.32M |
| Cash at Beginning | $3.23M | $7.57M | $13.38M | $53.96M | $58.23M | $102.62M | $0 | $0 | $0 | $0 |
| Cash at End | $3.24M | $3.23M | $7.57M | $13.38M | $53.96M | $58.23M | $102.62M | $0 | $0 | $0 |